Best length of daratumumab maintenance for light-chain (AL) amyloidosis
Official title: Evaluating Maintenance In Light chain Amyloidosis (EMILIA)
Funded at Mayo Clinic Rochester · NIH-11247977 · Data updated 2026-11-12
This project compares shorter (6 months) versus longer (18 months) daratumumab maintenance for people with AL amyloidosis who have responded to daratumumab-CyBorD induction.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | December 13, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2026 |
| Award (this year) | $188,695 |
| NIH project number | 5R21CA288898-02 |
| Project ID | NIH-11247977 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with AL (light-chain) amyloidosis who achieved an adequate hematologic response after daratumumab-CyBorD induction would be the ideal candidates.
✕Less likely to help
Patients who have not received daratumumab-CyBorD induction, who did not achieve a good hematologic response, or those with other non-AL forms of amyloidosis would not be expected to benefit from or be eligible for this trial.
What this research studies
If you have light-chain (AL) amyloidosis and achieved a good blood response after initial daratumumab-CyBorD therapy, this trial would randomly assign you to receive daratumumab maintenance for either 6 months or 18 months. Doctors will monitor blood markers, organ function, and side effects over time to see how long the response lasts and whether organs recover. The study uses a pragmatic design to reflect real-world care while comparing the two maintenance lengths. The goal is to find whether shorter maintenance can keep benefits while lowering treatment burden or whether longer maintenance gives better outcomes.
Why it matters
Potential benefit: If successful, this could show the optimal maintenance duration to preserve responses and organ recovery while potentially reducing treatment time and side effects.
How similar studies have gone: The phase III ANDROMEDA trial showed daratumumab-CyBorD induction improves hematologic responses but included non-randomized maintenance, so randomized evidence on optimal maintenance duration is currently lacking.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Kourelis, Taxiarchis — Mayo Clinic Rochester
- Study coordinator: Kourelis, Taxiarchis
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney-like blood flow may cause amyloid buildup
A research project uses tiny blood-flow devices to study how certain proteins misfold and form amyloid deposits in organs like the kidney and heart.
-
Blood test to detect ATTR amyloidosis earlier using a smart detection kit
A new blood test kit aims to detect ATTR amyloidosis early using a biomarker that appears in patients but not in healthy people.
-
Detection and measurement of amyloid in people carrying the V122I TTR gene variant
This research will look for early signs of heart-related amyloidosis in people with the V122I TTR gene variant using blood tests and a special imaging scan.
-
Identifying Hidden Cardiac Amyloidosis in Black V122I TTR Carriers
This project looks for early signs of heart damage in Black individuals who carry the V122I TTR variant and may benefit from new treatments if caught early.
-
Chip phosphorylation boosts breakdown of mutant TTR to help heart amyloidosis
A scientist-led project aims to help people with a heart disease caused by a mutant protein called transthyretin (TTR) by boosting the body’s protein-cleanup systems to remove the harmful TTR deposits.
-
Finding transthyretin heart amyloid from lumbar spine surgery tissue
This project looks for transthyretin (TTR) amyloid in tissue removed during lumbar spine surgery to find people who may later develop TTR cardiac amyloidosis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.